RE: Uddin in NYC?
Winer....when we file our Form S-1 we'll see what check box is actually checked and my guess is the first one will be. Great Point wants their securities registered in the States, you can bet your bottom dollar on that, and they'll be after more poste haste.
Big Pharma will not give up their bread and butter as easily as you suggest and even with INT islet cell neogenisis, drug market penetration will only account for a smaller percentage of overall global sales.
Some suggest we should narrow our pipeline, some suggest a robust diversified pipeline is attractive. Everyone has an opinion yet Dr. Cruz and Co. will hold fast to our business model......because that is what we've decided the major Capital Markets are persuing. We're working towards the Sustainable Competitive Advantage Hugh Cleland holds as the holy grail. I am in agreement.
INT will be stellar-positive efficacy wise but we learned early on in the trials that dosing titration for EGF is required for typel and typell and we also learned that Standardized Adult Dosing for EGF is required and not Weight-based Dosing. The INT part of the equation was as expected....... Will there be questions? Of course. But nothing that can't be worked out in a Phasellb.
The holdup has nothing to do with the results being good or bad or in between......it has to do with timing and available resources.